These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 29520688)

  • 21. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model.
    Kyle JL; Balsitis SJ; Zhang L; Beatty PR; Harris E
    Virology; 2008 Oct; 380(2):296-303. PubMed ID: 18774583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
    de Oliveira LC; Ribeiro AM; Albarnaz JD; Torres AA; Guimarães LFZ; Pinto AK; Parker S; Doronin K; Brien JD; Buller MR; Bonjardim CA
    Arch Virol; 2020 Mar; 165(3):671-681. PubMed ID: 31942645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of humanized BLT mice for analysis of dengue virus infection and antiviral drug testing.
    Frias-Staheli N; Dorner M; Marukian S; Billerbeck E; Labitt RN; Rice CM; Ploss A
    J Virol; 2014 Feb; 88(4):2205-18. PubMed ID: 24335303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Live attenuated vaccine: the first clinically approved dengue vaccine?
    Fink K; Shi PY
    Expert Rev Vaccines; 2014 Feb; 13(2):185-8. PubMed ID: 24350687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate.
    Chen HR; Lai YC; Yeh TM
    J Biomed Sci; 2018 Jul; 25(1):58. PubMed ID: 30037331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of type I interferon responses in dengue and severe dengue in children in Paraguay.
    Talarico LB; Byrne AB; Amarilla S; Lovera D; Vázquez C; Chamorro G; Acosta PL; Ferretti A; Caballero MT; Arbo A; Polack FP
    J Clin Virol; 2017 Dec; 97():10-17. PubMed ID: 29078078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research progress in the structure and function of dengue virus non-structural 1 protein].
    Chen Y; Ren RW; Liu JW
    Bing Du Xue Bao; 2014 Nov; 30(6):683-8. PubMed ID: 25868284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identifying protective dengue vaccines: guide to mastering an empirical process.
    Halstead SB
    Vaccine; 2013 Sep; 31(41):4501-7. PubMed ID: 23896423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-mediated cytokine storm and its role in severe dengue.
    Srikiatkhachorn A; Mathew A; Rothman AL
    Semin Immunopathol; 2017 Jul; 39(5):563-574. PubMed ID: 28401256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to dengue virus in the skin.
    Rathore APS; St John AL
    Open Biol; 2018 Aug; 8(8):. PubMed ID: 30135238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody avidity following secondary dengue virus type 2 infection across a range of disease severity.
    Lau L; Green AM; Balmaseda A; Harris E
    J Clin Virol; 2015 Aug; 69():63-7. PubMed ID: 26209381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological intervention for dengue virus infection.
    Lai JH; Lin YL; Hsieh SL
    Biochem Pharmacol; 2017 Apr; 129():14-25. PubMed ID: 28104437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.